May 14, 2019
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
May 02, 2019
Global Diabetic Neuropathy Drugs Market to 2023 - Key Vendors are Daiichi Sankyo Co, Eli Lilly and Co, Johnson & Johnson Services, Novartis, & Pfizer
Mar 28, 2019
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
Feb 28, 2019
American Regent Announces the Re-Introduction of Aminocaproic Acid Injection, USP; AP Rated and Therapeutically Equivalent to Amicar®*(1)
Feb 22, 2019
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
Feb 05, 2019
FDA Grants Priority Review for Daiichi Sankyo's New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
Jan 29, 2019
Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to "Get Iron Informed"
Jan 07, 2019
Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo
Dec 19, 2018
Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML
Dec 17, 2018
Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics
Dec 10, 2018
Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Cancer Therapies
Dec 05, 2018
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Dec 03, 2018
Comprehensive Analyses from Pivotal Phase 3 QuANTUM-R Study Demonstrate Consistent Overall Survival Benefit of Daiichi Sankyo's FLT3 Inhibitor Quizartinib in Patients with Relapsed/Refractory FLT3-ITD AML
Nov 27, 2018
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
Nov 21, 2018
FDA Grants Priority Review for Daiichi Sankyo's New Drug Application for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Nov 19, 2018
Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Nov 01, 2018
Daiichi Sankyo to Present Data from AML Franchise Including FLT3 Inhibitor Quizartinib at ASH Annual Meeting
Oct 23, 2018
Daiichi Sankyo, Inc. Publishes Second Edition of Pain Trends Report
Oct 17, 2018
Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Oct 03, 2018
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma